Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial
Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer’s disease. The pioneering trial, expected to start by early 2013, initially will test three promising drugs, each designed to target Alzheimer’s in different ways.
The investigational drugs are:
* Gantenerumab, an antibody made by Swiss drug major Roche (ROG: SIX) that binds to all forms of aggregated amyloid beta and helps remove them from the brain. Gantenerumab is currently in an international Phase III trial known as SCarlet RoAD, started in 2010, that will test the drug’s ability to stop Alzheimer’s prior to dementia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze